BioCryst Pharmaceuticals Cash on Hand 2010-2025 | BCRX

BioCryst Pharmaceuticals cash on hand from 2010 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
BioCryst Pharmaceuticals Annual Cash on Hand
(Millions of US $)
2024 $321
2023 $391
2022 $426
2021 $511
2020 $303
2019 $138
2018 $106
2017 $118
2016 $56
2015 $53
2014 $73
2013 $38
2012 $36
2011 $42
2010 $55
2009 $70
BioCryst Pharmaceuticals Quarterly Cash on Hand
(Millions of US $)
2025-03-31 $295
2024-12-31 $321
2024-09-30 $331
2024-06-30 $274
2024-03-31 $338
2023-12-31 $391
2023-09-30 $399
2023-06-30 $412
2023-03-31 $400
2022-12-31 $426
2022-09-30 $428
2022-06-30 $419
2022-03-31 $447
2021-12-31 $511
2021-09-30 $204
2021-06-30 $223
2021-03-31 $244
2020-12-31 $303
2020-09-30 $146
2020-06-30 $192
2020-03-31 $115
2019-12-31 $138
2019-09-30 $70
2019-06-30 $97
2019-03-31 $110
2018-12-31 $106
2018-09-30 $122
2018-06-30 $88
2018-03-31 $96
2017-12-31 $118
2017-09-30 $165
2017-06-30 $86
2017-03-31 $101
2016-12-31 $56
2016-09-30 $54
2016-06-30 $40
2016-03-31 $38
2015-12-31 $53
2015-09-30 $72
2015-06-30 $96
2015-03-31 $70
2014-12-31 $73
2014-09-30 $127
2014-06-30 $132
2014-03-31 $32
2013-12-31 $38
2013-09-30 $43
2013-06-30 $31
2013-03-31 $29
2012-12-31 $36
2012-09-30 $41
2012-06-30 $37
2012-03-31 $44
2011-12-31 $42
2011-09-30 $45
2011-06-30 $59
2011-03-31 $69
2010-12-31 $55
2010-09-30 $61
2010-06-30 $56
2010-03-31 $64
2009-12-31 $70
2009-09-30 $35
2009-06-30 $42
2009-03-31 $54
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $1.789B $0.451B
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $81.321B 31.28
Zoetis (ZTS) United States $67.725B 25.27
Daiichi Sankyo, - (DSNKY) Japan $46.412B 23.79
Takeda Pharmaceutical (TAK) Japan $46.074B 9.16
BeOne Medicines - (ONC) Cayman Islands $31.945B 0.00
Sandoz Group AG (SDZNY) Switzerland $26.145B 0.00
Summit Therapeutics (SMMT) United States $21.292B 0.00
Merck (MKKGY) Germany $17.234B 12.63
Shionogi (SGIOY) Japan $14.649B 14.68
United Therapeutics (UTHR) United States $13.735B 12.15
Neurocrine Biosciences (NBIX) United States $13.077B 44.79
Orion OYJ (ORINY) Finland $11.714B 28.23
IPSEN (IPSEY) France $10.870B 0.00
Stevanato Group S.p.A (STVN) Italy $8.028B 49.09
Corcept Therapeutics (CORT) United States $7.242B 58.87
Grifols, S.A (GRFS) Spain $6.944B 0.00
Ionis Pharmaceuticals (IONS) United States $6.724B 0.00
Madrigal Pharmaceuticals (MDGL) United States $6.625B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.204B 0.00
Ono Pharmaceutical (OPHLF) Japan $5.214B 15.86
Soleno Therapeutics (SLNO) United States $4.358B 0.00
Hypermarcas (HYPMY) Brazil $2.945B 19.38
Crinetics Pharmaceuticals (CRNX) United States $2.902B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.650B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.558B 8.96
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.526B 13.66
Centessa Pharmaceuticals (CNTA) United Kingdom $2.058B 0.00
Ocular Therapeutix (OCUL) United States $1.945B 0.00
Endo (NDOI) United States $1.812B 0.00
ARS Pharmaceuticals (SPRY) United States $1.755B 0.00
Evotec AG (EVO) Germany $1.513B 0.00
Harrow (HROW) United States $1.328B 0.00
Guardian Pharmacy Services (GRDN) United States $1.301B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.206B 24.14
Dyne Therapeutics (DYN) United States $1.131B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.067B 0.00
Enliven Therapeutics (ELVN) United States $1.040B 0.00
Ardelyx (ARDX) United States $1.026B 0.00
Collegium Pharmaceutical (COLL) United States $1.021B 5.51
Verve Therapeutics (VERV) United States $0.992B 0.00
ProKidney (PROK) United States $0.963B 0.00
Akebia Therapeutics (AKBA) United States $0.935B 0.00
Cronos Group (CRON) Canada $0.791B 0.00
Xeris Biopharma Holdings (XERS) United States $0.785B 0.00
KalVista Pharmaceuticals (KALV) United States $0.728B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.727B 0.00
Xencor (XNCR) United States $0.658B 0.00
Relay Therapeutics (RLAY) United States $0.641B 0.00
Organogenesis (ORGO) United States $0.638B 0.00
Zevra Therapeutics (ZVRA) United States $0.614B 0.00
USANA Health Sciences (USNA) United States $0.595B 11.97
Elite Pharmaceuticals (ELTP) United States $0.591B 0.00
Theravance Biopharma (TBPH) United States $0.552B 0.00
Bioventus (BVS) United States $0.540B 13.69
Oruka Therapeutics (ORKA) United States $0.534B 0.00
Siga Technologies (SIGA) United States $0.510B 10.66
Tourmaline Bio (TRML) United States $0.508B 0.00
Savara (SVRA) United States $0.446B 0.00
Aquestive Therapeutics (AQST) United States $0.412B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.366B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.360B 9.74
AleAnna (ANNA) United States $0.332B 0.00
Altimmune (ALT) United States $0.331B 0.00
Nanobiotix S.A (NBTX) France $0.321B 0.00
Nektar Therapeutics (NKTR) United States $0.310B 0.00
Aldeyra Therapeutics (ALDX) United States $0.310B 0.00
Esperion Therapeutics (ESPR) United States $0.299B 0.00
Heron Therapeutics (HRTX) United States $0.291B 0.00
Nature's Sunshine Products (NATR) United States $0.272B 24.93
OmniAb (OABI) United States $0.256B 0.00
Larimar Therapeutics (LRMR) United States $0.248B 0.00
Liminatus Pharma (LIMN) United States $0.227B 0.00
MediWound (MDWD) Israel $0.220B 0.00
4D Molecular Therapeutics (FDMT) United States $0.212B 0.00
China SXT Pharmaceuticals (SXTC) China $0.184B 0.00
Galectin Therapeutics (GALT) United States $0.184B 0.00
Aclaris Therapeutics (ACRS) United States $0.184B 0.00
Lyell Immunopharma (LYEL) United States $0.184B 0.00
Journey Medical (DERM) United States $0.177B 0.00
Profound Medical (PROF) Canada $0.171B 0.00
Avita Medical (RCEL) United States $0.153B 0.00
Korro Bio (KRRO) United States $0.150B 0.00
Lexeo Therapeutics (LXEO) United States $0.137B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.132B 0.00
Inhibikase Therapeutics (IKT) United States $0.132B 0.00
Protara Therapeutics (TARA) United States $0.128B 0.00
Cardiol Therapeutics (CRDL) Canada $0.119B 0.00
Cassava Sciences (SAVA) United States $0.114B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.113B 0.00
Innate Pharma SA (IPHYF) France $0.110B 0.00
Vivani Medical (VANI) United States $0.095B 0.00
Nutriband (NTRB) United States $0.095B 0.00
Fractyl Health (GUTS) United States $0.094B 0.00
Achieve Life Sciences (ACHV) Canada $0.093B 0.00
VAXART, INC (VXRT) United States $0.092B 0.00
Metagenomi (MGX) United States $0.091B 0.00
Champions Oncology (CSBR) United States $0.086B 19.50
ESSA Pharma (EPIX) Canada $0.083B 0.00
Arch Biopartners (ACHFF) Canada $0.078B 0.00
Pyxis Oncology (PYXS) United States $0.077B 0.00
Surrozen (SRZN) United States $0.077B 0.00
Inotiv (NOTV) United States $0.076B 0.00
Context Therapeutics (CNTX) United States $0.075B 0.00
Dominari Holdings (DOMH) United States $0.075B 0.00
Rafael Holdings (RFL) United States $0.074B 0.00
PMV Pharmaceuticals (PMVP) United States $0.073B 0.00
Avalo Therapeutics (AVTX) United States $0.072B 0.00
Assertio Holdings (ASRT) United States $0.071B 0.00
Wellgistics Health (WGRX) United States $0.068B 0.00
Telomir Pharmaceuticals (TELO) United States $0.065B 0.00
Unicycive Therapeutics (UNCY) United States $0.062B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.061B 0.00
ElectroCore (ECOR) United States $0.058B 0.00
Klotho Neurosciences (KLTO) United States $0.057B 0.00
Century Therapeutics (IPSC) United States $0.054B 0.00
Jupiter Neurosciences (JUNS) United States $0.054B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.053B 39.06
Prelude Therapeutics (PRLD) United States $0.053B 0.00
NRx Pharmaceuticals (NRXP) United States $0.052B 0.00
Gain Therapeutics (GANX) United States $0.051B 0.00
Acrivon Therapeutics (ACRV) United States $0.045B 0.00
Mural Oncology (MURA) Ireland $0.042B 0.00
Karyopharm Therapeutics (KPTI) United States $0.038B 0.00
PolyPid (PYPD) Israel $0.038B 0.00
Iterum Therapeutics (ITRM) Ireland $0.032B 0.00
Plus Therapeutics (PSTV) United States $0.032B 0.00
Incannex Healthcare (IXHL) Australia $0.031B 0.00
Vivos Therapeutics (VVOS) United States $0.031B 0.00
FibroGen (FGEN) United States $0.030B 0.00
Tempest Therapeutics (TPST) United States $0.029B 0.00
SCYNEXIS (SCYX) United States $0.028B 0.00
Enlivex Therapeutics (ENLV) Israel $0.027B 0.00
Scienture Holdings (SCNX) United States $0.026B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.023B 0.00
Natural Alternatives (NAII) United States $0.022B 0.00
VYNE Therapeutics (VYNE) United States $0.022B 0.00
Relmada Therapeutics (RLMD) United States $0.021B 0.00
Cosmos Health (COSM) United States $0.020B 0.00
ProPhase Labs (PRPH) United States $0.019B 0.00
Lipocine (LPCN) United States $0.018B 0.00
CASI Pharmaceuticals (CASI) China $0.018B 0.00
BioLineRx (BLRX) Israel $0.018B 0.00
Citius Pharmaceuticals (CTXR) United States $0.018B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.018B 0.00
DURECT (DRRX) United States $0.018B 0.00
Carisma Therapeutics (CARM) United States $0.016B 0.00
Mannatech (MTEX) United States $0.016B 0.00
Ernexa Therapeutics (ERNA) United States $0.014B 0.00
BioVie (BIVI) United States $0.014B 0.00
TherapeuticsMD (TXMD) United States $0.014B 0.00
Phio Pharmaceuticals (PHIO) United States $0.013B 0.00
Ainos (AIMD) United States $0.011B 0.00
Lyra Therapeutics (LYRA) United States $0.011B 0.00
Biomerica (BMRA) United States $0.010B 0.00
TransCode Therapeutics (RNAZ) United States $0.010B 0.00
Aptorum Group (APM) United Kingdom $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Mangoceuticals (MGRX) United States $0.009B 0.00
Traws Pharma (TRAW) United States $0.009B 0.00
Talphera (TLPH) United States $0.009B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.007B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Indaptus Therapeutics (INDP) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
InMed Pharmaceuticals (INM) Canada $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Alaunos Therapeutics (TCRT) United States $0.005B 0.00
Qualigen Therapeutics (QLGN) United States $0.005B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
SciSparc (SPRC) Israel $0.004B 0.00
SHINECO (SISI) China $0.004B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
PainReform (PRFX) Israel $0.003B 0.00
CERo Therapeutics Holdings (CERO) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Aditxt (ADTX) United States $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Conduit Pharmaceuticals (CDT) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
Indivior (INDV) United States $0.000B 10.02
4D Pharma (LBPS) United Kingdom $0.000B 0.00
MEI Pharma (MEIP) United States $0.000B 0.00
Minerva Neurosciences (NERV) United States $0.000B 2.60
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00